Trial
NCT06897579
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Extensive Stage Small Cell Lung Cancer
Intervention
Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule
Why stopped
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-28